SALT LAKE CITY and LEXINGTON, Mass., April 17, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) and RainDance Technologies, Inc. today announced that they have entered into a commercial agreement whereby Myriad will adopt RainDance's ThunderStorm™ Target Enrichment System for Myriad's next-generation sequencing based Hereditary Cancer Panel (HCP) test. As part of this agreement, Myriad and RainDance have signed a multi-year supply agreement where RainDance will provide Myriad with ThunderStorm systems, reagents, gene panels, and consumables.
Myriad Adopts RainDance's Thunderstorm Platform For Next-Generation Sequencing Based Hereditary Cancer Panel
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.